TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura
Inclusion criteria for randomization included 6 - 14 days of migraine per month as assessed by a headache specialist, and failure (either lack of efficacy or intolerance) of 3 preventive medications and a significant right to left cardiac shunt (Spencer grade 4-5) determined by a screening TransCran...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2015-10, Vol.66 (15), p.B13-B13 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | B13 |
|---|---|
| container_issue | 15 |
| container_start_page | B13 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 66 |
| creator | Tobis, Jonathan Charles, Andrew Silberstein, Stephen D Sorensen, Sherman Maini, Brij Horwitz, Phillip A Gurley, John c |
| description | Inclusion criteria for randomization included 6 - 14 days of migraine per month as assessed by a headache specialist, and failure (either lack of efficacy or intolerance) of 3 preventive medications and a significant right to left cardiac shunt (Spencer grade 4-5) determined by a screening TransCranial Doppler (TCD) intravenous agitated saline study. |
| doi_str_mv | 10.1016/j.jacc.2015.08.076 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1719455734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S073510971505038X</els_id><sourcerecordid>3829058631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2726-e4b10d1664c91ebccde1a5e49cb710812ba26d47f3b435cca09a073261ba45053</originalsourceid><addsrcrecordid>eNp9kd2K00AUgIMoWFdfwKsBr1Nnkkx-RIRSu-5CS8uaBfFmOJmcuBPTTHd-VvpMCz6ET-bEFgQvvDpwON_5-6LoNaNzRln-tp_3IOU8oYzPaTmnRf4kmjHOyzjlVfE0mtEi5TGjVfE8emFtTynNS1bNosd6WccpJbub1eb6dkNqo2B4Rz5q3wxImkGNLbHOt0eiO3JAI72DEbW3RA7aeoN_8uBwdKTTBvY4Ev0Agf2h3B1xd0gWm916UX9d3fz6SXaXW7KVcvAtGgKWAHEGwe3PONmrbwbUeKZDYoraOwLewMvoWQeDxVfneBHdXq7q5VW83n66Xi7WsUyKJI8xaxhtWZ5nsmLYSNkiA45ZJZuC0ZIlDSR5mxVd2mQplxJoBeE9Sc4ayDjl6UX05tT3YPS9R-tEr70Zw0jBClZlnBdpFqqSU5U02lqDnTgYtQdzFIyKSYroxSRFTFIELUWQEqD3JwjD_g8KjbBS4SixVQalE61W_8c__IPLYEhJGL7jEe3fNYVNBBWfJ-uTdBbOomn5Jf0NksKrJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1719455734</pqid></control><display><type>article</type><title>TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Tobis, Jonathan ; Charles, Andrew ; Silberstein, Stephen D ; Sorensen, Sherman ; Maini, Brij ; Horwitz, Phillip A ; Gurley, John c</creator><creatorcontrib>Tobis, Jonathan ; Charles, Andrew ; Silberstein, Stephen D ; Sorensen, Sherman ; Maini, Brij ; Horwitz, Phillip A ; Gurley, John c</creatorcontrib><description>Inclusion criteria for randomization included 6 - 14 days of migraine per month as assessed by a headache specialist, and failure (either lack of efficacy or intolerance) of 3 preventive medications and a significant right to left cardiac shunt (Spencer grade 4-5) determined by a screening TransCranial Doppler (TCD) intravenous agitated saline study.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2015.08.076</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Cardiology ; Cardiovascular ; Headaches ; Internal Medicine ; Migraine</subject><ispartof>Journal of the American College of Cardiology, 2015-10, Vol.66 (15), p.B13-B13</ispartof><rights>2015</rights><rights>Copyright Elsevier Limited Oct 13, 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2726-e4b10d1664c91ebccde1a5e49cb710812ba26d47f3b435cca09a073261ba45053</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S073510971505038X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids></links><search><creatorcontrib>Tobis, Jonathan</creatorcontrib><creatorcontrib>Charles, Andrew</creatorcontrib><creatorcontrib>Silberstein, Stephen D</creatorcontrib><creatorcontrib>Sorensen, Sherman</creatorcontrib><creatorcontrib>Maini, Brij</creatorcontrib><creatorcontrib>Horwitz, Phillip A</creatorcontrib><creatorcontrib>Gurley, John c</creatorcontrib><title>TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura</title><title>Journal of the American College of Cardiology</title><description>Inclusion criteria for randomization included 6 - 14 days of migraine per month as assessed by a headache specialist, and failure (either lack of efficacy or intolerance) of 3 preventive medications and a significant right to left cardiac shunt (Spencer grade 4-5) determined by a screening TransCranial Doppler (TCD) intravenous agitated saline study.</description><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Headaches</subject><subject>Internal Medicine</subject><subject>Migraine</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kd2K00AUgIMoWFdfwKsBr1Nnkkx-RIRSu-5CS8uaBfFmOJmcuBPTTHd-VvpMCz6ET-bEFgQvvDpwON_5-6LoNaNzRln-tp_3IOU8oYzPaTmnRf4kmjHOyzjlVfE0mtEi5TGjVfE8emFtTynNS1bNosd6WccpJbub1eb6dkNqo2B4Rz5q3wxImkGNLbHOt0eiO3JAI72DEbW3RA7aeoN_8uBwdKTTBvY4Ev0Agf2h3B1xd0gWm916UX9d3fz6SXaXW7KVcvAtGgKWAHEGwe3PONmrbwbUeKZDYoraOwLewMvoWQeDxVfneBHdXq7q5VW83n66Xi7WsUyKJI8xaxhtWZ5nsmLYSNkiA45ZJZuC0ZIlDSR5mxVd2mQplxJoBeE9Sc4ayDjl6UX05tT3YPS9R-tEr70Zw0jBClZlnBdpFqqSU5U02lqDnTgYtQdzFIyKSYroxSRFTFIELUWQEqD3JwjD_g8KjbBS4SixVQalE61W_8c__IPLYEhJGL7jEe3fNYVNBBWfJ-uTdBbOomn5Jf0NksKrJA</recordid><startdate>20151013</startdate><enddate>20151013</enddate><creator>Tobis, Jonathan</creator><creator>Charles, Andrew</creator><creator>Silberstein, Stephen D</creator><creator>Sorensen, Sherman</creator><creator>Maini, Brij</creator><creator>Horwitz, Phillip A</creator><creator>Gurley, John c</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20151013</creationdate><title>TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura</title><author>Tobis, Jonathan ; Charles, Andrew ; Silberstein, Stephen D ; Sorensen, Sherman ; Maini, Brij ; Horwitz, Phillip A ; Gurley, John c</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2726-e4b10d1664c91ebccde1a5e49cb710812ba26d47f3b435cca09a073261ba45053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Headaches</topic><topic>Internal Medicine</topic><topic>Migraine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tobis, Jonathan</creatorcontrib><creatorcontrib>Charles, Andrew</creatorcontrib><creatorcontrib>Silberstein, Stephen D</creatorcontrib><creatorcontrib>Sorensen, Sherman</creatorcontrib><creatorcontrib>Maini, Brij</creatorcontrib><creatorcontrib>Horwitz, Phillip A</creatorcontrib><creatorcontrib>Gurley, John c</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tobis, Jonathan</au><au>Charles, Andrew</au><au>Silberstein, Stephen D</au><au>Sorensen, Sherman</au><au>Maini, Brij</au><au>Horwitz, Phillip A</au><au>Gurley, John c</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2015-10-13</date><risdate>2015</risdate><volume>66</volume><issue>15</issue><spage>B13</spage><epage>B13</epage><pages>B13-B13</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>Inclusion criteria for randomization included 6 - 14 days of migraine per month as assessed by a headache specialist, and failure (either lack of efficacy or intolerance) of 3 preventive medications and a significant right to left cardiac shunt (Spencer grade 4-5) determined by a screening TransCranial Doppler (TCD) intravenous agitated saline study.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jacc.2015.08.076</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2015-10, Vol.66 (15), p.B13-B13 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_journals_1719455734 |
| source | Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Cardiology Cardiovascular Headaches Internal Medicine Migraine |
| title | TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T06%3A30%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TCT-30%20PREMIUM%20Trial:%20Double%20blind%20study%20of%20percutaneous%20closure%20of%20patent%20foramen%20ovale%20with%20the%20AMPLATZER%C2%AE%20PFO%20Occluder%20as%20a%20treatment%20for%20migraine%20with%20or%20without%20aura&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Tobis,%20Jonathan&rft.date=2015-10-13&rft.volume=66&rft.issue=15&rft.spage=B13&rft.epage=B13&rft.pages=B13-B13&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2015.08.076&rft_dat=%3Cproquest_cross%3E3829058631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1719455734&rft_id=info:pmid/&rft_els_id=1_s2_0_S073510971505038X&rfr_iscdi=true |